View all newsletters
At the 15th International Virtual Conference on Alzheimer’s disease (AD) and Parkinson’s disease (PD) 2021, a clinical-stage biotech company based…
By
On March 4, Galapagos announced pooled interim results from its ongoing MANTA and MANTA-RAy testicular safety studies for Jyseleca (filgotinib)…
With new SARS-CoV-2 variant strains appearing, the global race to control the COVID-19 pandemic through immunization is on. Europe remains…
With the Covid-19 pandemic recently passing one year in duration, clinical research continues to be significantly affected. The most prominent…
By On 5th February, AstraZeneca announced that its Phase III KESTREL clinical trial (NCT02551159) failed to achieve its primary endpoint for…
By
On February 10, Gilead and Galapagos announced the discontinuation of the ISABELA Phase III clinical trials investigating ziritaxestat, a once-daily…
By
On January 27, Pfizer announced co-primary endpoint results from ORAL Surveillance (NCT02092467), a required post-marketing safety study of the Janus…
On January 21, AriBio, a biopharmaceutical company based in South Korea, announced the completion of a Phase II clinical trial…
By